Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
Key Highlights
- ➤Ardelyx will present three hyperphosphatemia abstracts at ASN Kidney Week 2026
- ➤Posters include real-world tenapanor outcomes by phosphate-binder use
- ➤Research covers patient perspectives and cumulative hyperphosphatemia morbidity and mortality risks
- ➤Samuel A. Kantor will discuss XPHOZAH mechanism, efficacy, safety, and practical use
- ➤XPHOZAH diarrhea occurred in 43-53% of treated patients across trials
Expert Statements
Samuel A. Kantor, Leading nephrologist
“Expanding Perspectives in Hyperphosphatemia Treatment: A Different Approach”
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced three abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21–25, 2026 in Denver, Colorado.
The poster presentations will highlight new research pertaining to the hyperphosphatemia treatment landscape, including real-world evidence evaluating the effectiveness of tenapanor with different phosphate binders, patient perspectives on the challenges of managing hyperphosphatemia, and an analysis of the impact long-term hyperphosphatemia has on morbidity and mortality among patients on dialysis.
Get started
Create a free account to read the full story.